Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Obinutuzumab> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- Obinutuzumab abstract "Obinutuzumab (called afutuzumab until 2009) is a humanized monoclonal antibody, originated by Glycart Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma. It acts as an immunomodulator.Obinutuzumab targets CD20 and kills B cells.Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.".
- Obinutuzumab atcPrefix "L01".
- Obinutuzumab atcSuffix "XC15".
- Obinutuzumab casNumber "949142-50-1".
- Obinutuzumab fdaUniiCode "O43472U9X8".
- Obinutuzumab wikiPageID "19841411".
- Obinutuzumab wikiPageRevisionID "589943149".
- Obinutuzumab atcPrefix "L01".
- Obinutuzumab atcSuffix "XC15".
- Obinutuzumab c "6512".
- Obinutuzumab casNumber "949142".
- Obinutuzumab chemspiderid "NA".
- Obinutuzumab eliminationHalfLife "2453760.0".
- Obinutuzumab h "10060".
- Obinutuzumab kegg "D09321".
- Obinutuzumab legalUs "Rx-only".
- Obinutuzumab mabType "mab".
- Obinutuzumab molecularWeight "146.1".
- Obinutuzumab n "1712".
- Obinutuzumab o "2020".
- Obinutuzumab s "44".
- Obinutuzumab source "zu/o".
- Obinutuzumab target CD20.
- Obinutuzumab type "mab".
- Obinutuzumab unii "O43472U9X8".
- Obinutuzumab verifiedfields "changed".
- Obinutuzumab verifiedrevid "477243496".
- Obinutuzumab subject Category:Hoffmann-La_Roche.
- Obinutuzumab type Drug.
- Obinutuzumab type FunctionalSubstance.
- Obinutuzumab comment "Obinutuzumab (called afutuzumab until 2009) is a humanized monoclonal antibody, originated by Glycart Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma. It acts as an immunomodulator.Obinutuzumab targets CD20 and kills B cells.Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients.".
- Obinutuzumab label "Afutuzumab".
- Obinutuzumab label "Afutuzumab".
- Obinutuzumab label "Obinutuzumab".
- Obinutuzumab label "أوبينوتوزوماب".
- Obinutuzumab sameAs Afutuzumab.
- Obinutuzumab sameAs Afutuzumab.
- Obinutuzumab sameAs m.04q2lbw.
- Obinutuzumab sameAs Q389496.
- Obinutuzumab sameAs Q389496.
- Obinutuzumab wasDerivedFrom Obinutuzumab?oldid=589943149.
- Obinutuzumab isPrimaryTopicOf Obinutuzumab.